Sanofi’s Dupixent successor heads to regulators after Phase III success
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic…
Dermatology
-
-
New data links eczema to inflammatory bowel and eye conditions
Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact…
-
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata.…
-
MoonLake’s IL-17 inhibitor falls short of Bimzelx in HS trial
MoonLake Immunotherapeutics’s stock has crashed after its hidradenitis suppurativa (HS) candidate did not beat UCB’s Bimzelx (bimekizumab-bkz) in a pair…
-
J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu
Johnson & Johnson (J&J) and Protagonist Therapeutics’ icotrokinra has outperformed BMS’s Sotyktu (deucravacitinib) in treating patients with moderate-to-severe plaque psoriasis.…
-
EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial
Sanofi’s brivekimig met the primary endpoint in a Phase IIa trial in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa…
-
Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial
Amgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational T-cell rebalancing…
-
Novartis culls ianalumab in HS after Phase IIb trial failure
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet…
-
LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial
LEO Pharma has reported positive outcomes from the 16-week interim analysis of the randomised Phase IIIb ADHAND trial of fully…
-
Nektar’s stock doubles on eczema therapy success in Phase IIb study
Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin (rezpeg)…
